2022-11-20T02:55:09+03:00[Europe/Moscow] en true <p>Standard Chemotherapy </p>, <p>Targeted therapeutics</p>, <p>cytostatic</p>, <p>D</p>, <p>C</p>, <p>A</p>, <p>pancreatic, liver, lung, esophagus </p>, <p>In situ</p>, <p>Localized</p>, <p>Regional</p>, <p>Distant</p>, <p>Cell competition</p>, <p>capecitabine (xeldoa) ; Carboxlesterase; 5-fu</p>, <p>1-5%; DPD; FUH2</p>, <p>DPYD; rate-limiting</p>, <p>True</p>, <p>1 normal function + 1 no function allele or 1 decreased function; 2 decreased function alleles </p>, <p>2 no function alleles; 1 no function + 1 decreased function </p>, <p>SERMs, growth inhibitor, prodrug, </p>, <p>HR+; pre &amp; post menopausal women</p>, <p>ER+ &amp; HER2-</p>, <p>prevents ER signaling in cancer cells by binding to ER- resulting in receptor dimerization and causing an inactive complex; results in decreased ER signaling </p>, <p>CYP2D6, CYP3A4/5, CYP3A4/5, CYP2D6</p>, <p>d,e </p>, <p>b, c</p> flashcards
Module 3-Slide deck 2: Oncology Lite

Module 3-Slide deck 2: Oncology Lite

Customize
collection saved
Share
Long Term Learning Spaced Repetition
Add to Long Term Learning Desk
Fast learning Repeat this set of flashcards
Preview Test Spell
Play
Match
Review

  • Standard Chemotherapy

    -acts on all rapidly dividing normal and cancerous cells

    -cytotoxic

  • Targeted therapeutics

    -act on specific molecular targets that are associated with cancer

    -designed to interact with a defined molecular target

    -cytostatic

    -represented by small molecules or biologics

  • cytostatic

    -block tumor cell growth or proliferation

  • D

    What cancer affects men the most?

    a) lung & bronchus

    b) colon & rectum

    c) breast

    d) prostate

  • C

    Which cancer affects women the most?

    a) lung & bronchus

    b) colon & rectum

    c) breast

    d) thyroid

  • A

    Which cancer has the highest mortality rate?

    a) lung & bronchus

    b) colon & rectum

    c) breast

    d) thyroid

  • pancreatic, liver, lung, esophagus

    What are the most lethal cancers? Order from most lethal to least.

  • In situ

    -early cancer that is present only in the layer of cells in which it began

  • Localized

    -cancer that is limited to the organ in which it began, without evidence of spread

  • Regional

    -cancer that spread beyond the original (primary) site to nearby lymph nodes or organs and tissues.

  • Distant

    -cancer that has spread from the primary site to distant organs or distant lymph nodes

  • Cell competition

    a term used to describe when cancer cells proliferate and kill surrounding wild-type cells via apoptosis so that the total cell number does not change.

  • capecitabine (xeldoa) ; Carboxlesterase; 5-fu

    __________ is the prodrug or inactive form. It is metabolized by _______ into it's active form ______________.

  • 1-5%; DPD; FUH2

    What percentage of 5-FU is converted in the body? What enzyme converts in into its inactive metabolite? What is the inactive metabolite?

  • DPYD; rate-limiting

    _________ gene encodes dihydropyrimidine dehydrogenase (DPD), an enzyme that catalyzes the ______________ step in fluoropyrimidine metabolism.

  • True

    The FDA-approved drug label for 5-fluorouracil states that no dose has been proven safe in individuals with absent DPD activity. T/F?

  • 1 normal function + 1 no function allele or 1 decreased function; 2 decreased function alleles

    DPYD intermediate metabolizer

  • 2 no function alleles; 1 no function + 1 decreased function

    DPYD poor metabolizer

  • SERMs, growth inhibitor, prodrug,

    Tamoxifen

    - drug class

    -active or prodrug

  • HR+; pre & post menopausal women

    Tamoxifen is used for the treatment of both early and advanced ______ and _____________.

  • ER+ & HER2-

    What groups do we have targeted therapeutics for in breast cancer patients?

  • prevents ER signaling in cancer cells by binding to ER- resulting in receptor dimerization and causing an inactive complex; results in decreased ER signaling

    Explain tamoxifen moa.

  • CYP2D6, CYP3A4/5, CYP3A4/5, CYP2D6

    A-B-C-D-

    A-

    B-

    C-

    D-

  • d,e

    Which drug(s) is a strong inhibitor of CYP2D6; thus interfering with Tamoxifen metabolism?

    a) Venlaflaxine

    b) Setraline

    c) sitalopram

    d) fluoxetine

    e) paroxetine

  • b, c

    Which drug(s) is a weak inhibitor of CYP2D6; thus interfering with Tamoxifen metabolism?

    a) Venlaflaxine

    b) Setraline

    c) citalopram

    d) fluoxetine

    e) paroxetine